WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION
- Cardiomyopathy: Myocardial damage, including acute left ventricular failure, can occur with doxorubicin hydrochloride. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1%–20% for cumulative doses ranging from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride [see Warnings and Precautions (5.1)].
- Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride [see Warnings and Precautions (5.2)].
- Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. Immediately terminate the drug and apply ice to the affected area [see Warnings and Precautions (5.3)].
- Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions (5.4)]. WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning.
- Cardiomyopathy: Myocardial damage can occur with doxorubicin hydrochloride with incidences from 1%–20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin hydrochloride is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with doxorubicin hydrochloride. (5.1)
- Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin hydrochloride. (5.2)
- Extravasation and Tissue Necrosis: Extravasation of doxorubicin hydrochloride can result in severe local tissue injury and necrosis requiring wide excision and skin grafting. Immediately terminate the drug, and apply ice to the affected area. (5.3)
- Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur. (5.4)
Use: Labeled indications
- as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer
- for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated:
- as a component of multi‑agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1)
- for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2) 1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. 1.2 Other Cancers Doxorubicin Hydrochloride Injection is indicated for the treatment of
- acute lymphoblastic leukemia
- acute myeloblastic leukemia
- Hodgkin lymphoma
- non-Hodgkin lymphoma (NHL)
- metastatic breast cancer
- metastatic Wilms' tumor
- metastatic neuroblastoma
- metastatic soft tissue sarcoma
- metastatic bone sarcoma
- metastatic ovarian carcinoma
- metastatic transitional cell bladder carcinoma
- metastatic thyroid carcinoma
- metastatic gastric carcinoma
- metastatic bronchogenic carcinoma
Contraindications
4 CONTRAINDICATIONS Doxorubicin Hydrochloride Injection are contraindicated in patients with:
- Severe myocardial insufficiency [see Warnings and Precautions (5.1)]
- Recent (occurring within the past 4-6 weeks) myocardial infarction [see Warnings and Precautions (5.1)]
- Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4)]
- Severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5)]
- Severe hypersensitivity reaction to doxorubicin hydrochloride, including anaphylaxis [see Adverse Reactions (6.2)]
- Severe myocardial insufficiency (4)
- Recent myocardial infarction (4)
- Severe persistent drug-induced myelosuppression (4)
- Severe hepatic impairment (4)
- Severe hypersensitivity to doxorubicin hydrochloride (4)
Dosing: Adult
- • Single agent: 60 to 75 mg/m 2 given intravenously every 21 days (2.2)
- • In combination: 40 to 75 mg/m 2 given intravenously every 21 to 28 days (2.2)
- • Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy (2.3)
- • Reduce dose in patients with hepatic impairment (2.4)
2.1 Recommended Dosage for Adjuvant Breast Cancer
2.1 Recommended Dosage for Adjuvant Breast Cancer The recommended dosage of Doxorubicin Hydrochloride Injection is 60 mg/m 2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles.
2.2 Recommended Dosage for Other Cancers
2.2 Recommended Dosage for Other Cancers
- The recommended dosage of Doxorubicin Hydrochloride Injection when used as a single agent is 60 mg/m 2 to 75 mg/m 2 intravenously every 21 days.
- The recommended dosage of Doxorubicin Hydrochloride Injection, when administered in combination with other chemotherapy drugs, is 40 mg/m 2 to 75 mg/m 2 intravenously every 21 to 28 days.
- Consider use of the lower Doxorubicin Hydrochloride Injection dose in the recommended dosage range or longer intervals between cycles for heavily pretreated patients, elderly patients, or obese patients.
- Cumulative doses above 550 mg/m 2 are associated with an increased risk of cardiomyopathy [see Warnings and Precautions (5.1)].
2.3 Dosage Modifications for Adverse Reactions Cardiomyopathy
2.3 Dosage Modifications for Adverse Reactions Cardiomyopathy Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy [see Warnings and Precautions (5.1)].
2.4 Dosage Modifications for Hepatic Impairment
2.4 Dosage Modifications for Hepatic Impairment Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C or serum bilirubin greater than 5 mg/dL) [see Contraindications (4)]. Dosage modifications for Doxorubicin Hydrochloride Injection in patients with elevated serum total bilirubin concentrations [see Warnings and Precautions (5.5), Use in Specific Populations (8.6)] are provided in Table 1.
Table 1. Recommended Dosage Modification for Elevated Serum Total Bilirubin Serum Total Bilirubin Concentration Dosage Modification 1.2–3 mg/dL 50% 3.1–5 mg/dL 75% Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection; discontinue Doxorubicin Hydrochloride Injection
2.5 Preparation and Administration
2.5 Preparation and Administration Doxorubicin Hydrochloride Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Preparation Dilution of Doxorubicin Hydrochloride Injection
- Dilute Doxorubicin Hydrochloride Injection in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP.
- Protect from light following preparation until completion of infusion.
- Use within 1 hour. If not used within 1 hour, discard the diluted product. Administration
- Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the solution is discolored, cloudy, or contains particulate matter. Administration by Intravenous Injection
- Administer diluted Doxorubicin Hydrochloride Injection as an intravenous injection through a central intravenous line or a secure and free-flowing peripheral venous line containing 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP.
- Administer intravenously over 3 to 10 minutes. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur. Administration by Continuous Intravenous Infusion
- Administer diluted Doxorubicin Hydrochloride Injection solution only through a central intravenous line. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur.
- Protect from light from preparation for infusion until completion of infusion. Management of Suspected Extravasation Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation. Manage confirmed or suspected extravasation as follows:
- Do not remove the needle until attempts are made to aspirate extravasated fluid.
- Do not flush the line.
- Avoid applying pressure to the site.
- Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days.
- If the extravasation is in an extremity, elevate the extremity.
- In adults, consider administration of dexrazoxane [see Warnings and Precautions (5.3)]. Management of Contact with Skin or Eyes Treat accidental contact with the skin or eyes immediately by copious lavage with water, or soap and water, or sodium bicarbonate solution. Do not abrade the skin by using a scrub brush. Seek medical attention. Incompatibility with Other Drugs Do not admix Doxorubicin Hydrochloride Injection with other drugs. If Doxorubicin Hydrochloride Injection is mixed with heparin or fluorouracil, a precipitate may form. Avoid contact with alkaline solutions which can lead to hydrolysis of doxorubicin hydrochloride.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment The clearance of doxorubicin was reduced in patients with elevated serum total bilirubin levels. Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin levels greater than 5 mg/dL) [see Contraindications (4)]. Reduce the dose of Doxorubicin Hydrochloride Injection in patients with serum total bilirubin levels greater than 1.2 mg/dL [See Dosage and Administration (2.4), Warnings and Precautions (5.5)].
2.4 Dosage Modifications for Hepatic Impairment Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (Child-Pugh Class C or serum bilirubin greater than 5 mg/dL) [see Contraindications (4)]. Dosage modifications for Doxorubicin Hydrochloride Injection in patients with elevated serum total bilirubin concentrations [see Warnings and Precautions (5.5), Use in Specific Populations (8.6)] are provided in Table 1.
Table 1. Recommended Dosage Modification for Elevated Serum Total Bilirubin Serum Total Bilirubin Concentration Dosage Modification 1.2–3 mg/dL 50% 3.1–5 mg/dL 75% Greater than 5 mg/dL Do not initiate Doxorubicin Hydrochloride Injection; discontinue Doxorubicin Hydrochloride Injection
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Based on postmarketing reports, pediatric patients treated with doxorubicin hydrochloride are at risk for developing late cardiovascular dysfunction. Risk factors include young age at treatment (especially < 5 years), high cumulative doses and receipt of combined modality therapy. Long-term periodic cardiovascular monitoring is recommended for all pediatric patients who have received doxorubicin hydrochloride.
Doxorubicin hydrochloride, as a component of intensive chemotherapy regimens administered to pediatric patients, may contribute to prepubertal growth failure and may also contribute to gonadal impairment, which is usually temporary. There are no recommended dose adjustments based on age. Doxorubicin clearance was increased in patients aged 2 years to 20 years as compared to adults, while doxorubicin clearance was similar in infants less than 2 years as compared to adults [see Clinical Pharmacology (12.3)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical experience in patients who were 65 years of age and older who received doxorubicin hydrochloride-based chemotherapy regimens for metastatic breast cancer showed no overall differences in safety and effectiveness compared with younger patients.
Administration
2.5 Preparation and Administration Doxorubicin Hydrochloride Injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Preparation Dilution of Doxorubicin Hydrochloride Injection • Dilute Doxorubicin Hydrochloride Injection in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. • Protect from light following preparation until completion of infusion. • Use within 1 hour. If not used within 1 hour, discard the diluted product. Administration • Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if the solution is discolored, cloudy, or contains particulate matter. Administration by Intravenous Injection • Administer diluted Doxorubicin Hydrochloride Injection as an intravenous injection through a central intravenous line or a secure and free-flowing peripheral venous line containing 0.9% Sodium Chloride Injection, USP, 0.45% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP. • Administer intravenously over 3 to 10 minutes. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur. Administration by Continuous Intravenous Infusion • Administer diluted Doxorubicin Hydrochloride Injection solution only through a central intravenous line. Decrease the rate of infusion if erythematous streaking along the vein proximal to the site of infusion or facial flushing occur. • Protect from light from preparation for infusion until completion of infusion. Management of Suspected Extravasation Immediately discontinue Doxorubicin Hydrochloride Injection for burning or stinging sensation or other evidence indicating peri-venous infiltration or extravasation. Manage confirmed or suspected extravasation as follows: • Do not remove the needle until attempts are made to aspirate extravasated fluid. • Do not flush the line. • Avoid applying pressure to the site. • Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days. • If the extravasation is in an extremity, elevate the extremity. • In adults, consider administration of dexrazoxane [see Warnings and Precautions (5.3) ] . Management of Contact with Skin or Eyes Treat accidental contact with the skin or eyes immediately by copious lavage with water, or soap and water, or sodium bicarbonate solution. Do not abrade the skin by using a scrub brush. Seek medical attention. Incompatibility with Other Drugs Do not admix Doxorubicin Hydrochloride Injection with other drugs. If Doxorubicin Hydrochloride Injection is mixed with heparin or fluorouracil, a precipitate may form. Avoid contact with alkaline solutions which can lead to hydrolysis of doxorubicin hydrochloride.
US FDA labelDosage forms
Philippines
- Lyophilized powder for injection: 10 mg, 50 mg
- Solution for injection: 2 mg/mL
- Lyophilized powder for iv injection/infusion: 10 mg, 50 mg
- ) solution for injection: 2 mg/mL (10 mg/5 mL, 2 mg/mL (50 mg/25 mL, 10 mg/5 mL (2 mg/mL
- ) solution for liposomal injection: 2 mg/mL (20 mg/10 mL, 2 mg/mL (50 mg/25 mL
- Lyophilized powder for injection for i.v. infusion: 10 mg, 50 mg
- Lyophilized powder for intravenous injection: 10 mg, 50 mg
- ) concentrate solution for iv infusion: 2 mg/mL (50 mg/25 mL
- ) pegylated liposomal concentrate for solution for injection: 2 mg/mL (20 mg/10 mL
- ) pegylated liposomal concentrate solution for i.v. infusion: 2 mg/mL (20 mg/10 mL
and 10 more forms; see the products table.
Registered products in the Philippines
77 products registered with the Food and Drug Administration (FDA) Philippines list Doxorubicin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products77
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AD MycinDoxorubicin Hydrochloride | 2 mg/mL Solution for Injection (IV)USP Type I Clear and Colorless glass vial x 5 mL and 25 mL (Box of 10's) | RxVAT-exempt | Boryung Pharmaceutical Co., LtdRepublic of Korea | Endure Medical, Inc. | DR-XY32895 | Feb 1, 2029 | |
Adriblastina RDDoxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (IV)25 mL-Capacity Type I Colorless Glass Vial with chlorobutyl Rubber stopper and Aluminum Seal with a Polypropylene Flip-off Top (Box of 1's) | RxVAT-exempt | Corden Pharma Latina S.P.A.italy | Importer: Pfizer, Inc. | DRP-3413 | Feb 9, 2028 | |
AdrimDoxorubicin hydrochloride | 2 mg/mL Solution for injection (I.V. Infusion)USP Type I Clear Glass Vial x 5 mL (Box of 1's); USP Type I Clear Glass Vial x 30 mL (25 mL net content) (Box of 1's) | RxVAT-exempt | Fresenius Kabi Oncology LimitedIndia | Fresenius Kabi Philippines Inc. | DR-XY42324 | Jul 31, 2028 | |
AdrycinDoxorubicin hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrate Suspension for Injection (I.V. Infusion)USP Type I glass vial with gray color rubber stopper and white color flip off seal x 10 mL (Box of 1's) | RxVAT-exempt | Hetero Labs Limited (Unit VI)India | Camber Pharmaceuticals, Inc. | DRP-15770 | Sep 12, 2029 | |
Anthra-50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (I.V.)30 mL-Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Magenta colored Aluminum Flip-Off Seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | — | DRP-13423 | Feb 15, 2028 | |
AxbinDoxorubicin hydrochloride | 50 mg Lyophilized Powder for Injection (I.V.)Type I colorless glass vial with bromobutyl rubber stopper and sealed with red aluminum cap x 40 mL (Box of 1’s) | RxVAT-exempt | Korea United Pharm. Inc.Korea | Qualimed Pharma Inc. | DR-XY49223 | Sep 24, 2029 | |
AxibinDoxorubicin hydrochloride | 10mg Lyophilized Powder for Injection (IV)USP Type I Clear, Colorless Glass Vial (Box of 1's) | RxVAT-exempt | Korea United Pharm. Inc.Korea | Qualimed Pharma Inc. | DR-XY49520 | Sep 16, 2030 | |
AxibinDoxorubicin hydrochloride | 2 mg/mL Solution for Injection (I.V.)USP Type I Clear, Colorless Glass Vial x 5 mL and 25 mL (Box of 1's) | RxVAT-exempt | Korea United Pharm. Inc.Republic of Korea | Qualimed Pharma Inc. | DR-XY31187 | Oct 18, 2031 | |
BDLYPODoxorubicin Hydrochloride | 2 mg/mL (20 mg/mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Net Content) (Box of 1’s) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Pharma 518, Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd. | DRP-7095 | Jan 16, 2032 | |
BicindoxilDoxorubicin hydrochloride | 2 mg/mL Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net Content of 5 mL and 25 mL, respectively (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-4794-05 | Oct 7, 2028 | |
ChemodoxDoxorubicin Hydrochloride | 2 mg/mL Pegylated Liposomal Concentrate Solution for IV InfusionUSP Type I Tubular glass vial with 20 mm bromobutyl rubber stopper and 20 mm light blue flip off seal x 10 mL (Box of 1's) | RxVAT-exempt | Sun Pharmaceutical Industries Ltd.India | Sun Pharma Philippines, Inc. | DRP-8740 | Feb 5, 2028 | |
D-Xobin 10Doxorubicin hydrochloride | 2 mg/mL (10 mg/5 mL) Solution for Injection (I.V.)USP Type I amber-colored tubular glass vial sealed with 20 mm grey bromo butyl rubber plug, aluminum seal, and 20 mm red flip off cap x 5 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Delex Pharma International, Inc.Importer: Aglobal Care, Inc. | DRP-9148-01 | Oct 10, 2031 | |
D-Xobin 50Doxorubicin hydrochloride | 2 mg/mL (50 mg/25 mL) Solution for Injection (I.V.)USP Type I amber-colored tubular glass vial sealed with 20 mm grey bromo butyl rubber plug, aluminum seal, and 20 mm red flip off cap x 25 mL (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Delex Pharma International, Inc.Importer: Aglobal Care, Inc. | DRP-9229-01 | Nov 19, 2031 | |
DactorubinDoxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (I.V.)Flint Tubular Type I Glass Vial with 20 mm Slotted GBBR Stopper and sealed with White Flip-Off Aluminum Seal x 5 mL (Box of 1's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-10196 | Oct 1, 2031 | |
DactorubinDoxorubicin (as Hydrochloride) | 50 mg Lyophilized Powder for Injection (IV)Flint Tubular Type I Glass Vial x 25 mL with 20 mm Slotted GBBR Stopper and Sealed with White Flip-Off Aluminum Seal (Box of 1's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-10197 | Oct 1, 2031 | |
Dobucin-50Doxorubicin hydrochloride | 50 mg Lyophilized Powder for Injection (IV)30 mL capacity USP Type I clear and colorless glass vial sealed with bromobutyl rubber stopper and red flip-off seal (Box of 1's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-7540 | Dec 7, 2027 | |
DorugemDoxorubicin hydrochloride | 2 mg/mL Solution for Injection (I.V.)30 mL Type I Amber Glass Vial with Net Content of 25 mL (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-4794-02 | Oct 7, 2028 | |
DoxGet-50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder For Injection (IV)30 mL -capacity USP Type I Clear Glass Vial with Grey Bromobutyl rubber stooper and Aluminum flip-off seal (Box of 1's) | RxVAT-exempt | Beta Drugs LimitedIndia | 2MG Incorporated | DRP-18282 | Jun 4, 2031 | |
Doxilyd 10Doxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc. | DRP-2299 | Jul 2, 2028 | |
Doxilyd 50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial with Rubber Stopper and Red Flip-off Seal Box of 1's | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc. | DRP-2300 | Jul 2, 2028 | |
DoxobicinDoxorubicin hydrochloride | 2 mg/mL Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net Content of 5 mL and 25 mL, respectively Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-4794-06 | Oct 7, 2028 | |
DoxocareDoxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV)USP Type I Tubular Flint Vial with red Flip-off cap (Box of 1's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. IncImporter: Multicare Pharmaceuticals Phils. Inc. | DRP-2741 | Mar 5, 2031 | |
DoxocareDoxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (IV)USP Type I Tubular Flint vial with red Flip-off cap (Box of 1's) | RxVAT-exempt | Naprod Life Sciences Pvt. Ltd.India | Multicare Pharmaceuticals Phils. Inc. | DRP-2718 | Mar 4, 2031 | |
Doxoccord 20 LPDoxorubicin Hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrate for Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper with Blue Flip-Off Seal Cap x 10 mL (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Importer: Accord Healthcare Limited-Philippine Branch Office | DRP-10846 | Dec 6, 2026 | |
Doxoccord 50 LPDoxorubicin Hydrochloride | 2 mg/mL (50 mg/25 mL) Pegylated Liposomal Concentrate Solution for Injection (IV Infusion)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper with Red Flip-Off Seal Cap x 30 mL (Net content: 25 mL) (Box of 1's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited - Philippine BranchImporter: Accord Healthcare Limited-Philippine Branch Office | DRP-10845 | Dec 6, 2026 | |
DoxoHealth 10Doxorubicin Hydrochloride | 10 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial with pink cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8962-02 | Aug 8, 2028 | |
DoxoHealth 50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial with Pink Cover (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8425-03 | Aug 8, 2028 | |
Doxonish-10Doxorubicin Hydrochloride | 10 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial in white opaque PVC blister tray with transparent cover (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-8962 | Aug 8, 2028 | |
Doxonish-50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial in white opaque PVC blister tray with transparent cover Box of 1 's | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DR-XY42394 | Aug 8, 2028 | |
Doxonorm-10Doxorubicin hydrochloride | 10 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-10989 | Dec 29, 2031 | |
Doxonorm-50Doxorubicin hydrochloride | 50 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Pharma 518, Inc.Importer: Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-10967 | Jan 17, 2032 | |
DoxorubaDoxorubicin hydrochloride | 2 mg/mL Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial (Box of 1’s) with Net Content of 5 mL and 25 mL, respectively | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambica International Corporation | DRP-4794 | Oct 7, 2028 | |
DoxoruceenDoxorubicin hydrochloride | 50 mg Lyophilized Powder for Injection (IV)30 mL capacity USP Type I clear and colorless glass vial sealed with bromobutyl rubber stopper and red flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Noble Pharma Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-7540-01 | Dec 7, 2027 | |
DoxrucinDoxorubicin Hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Box of 1’s) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd. | DRP-7095-03 | Jan 16, 2037 | |
Doxstar 10Doxorubicin Hydrochloride | 10 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial in white opaque PVC Blister tray with transparent cover (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8962-01 | Aug 8, 2028 | |
Doxstar 50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection/InfusionUSP Type I Clear and Colorless Glass Vial in White Opaque PVC Blister Tray with Transparent Cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-8425-01 | Aug 8, 2028 | |
Doxvex 50Doxorubicin Hydrochloride | 50 mg Powder for Injection (IV)USP Type I Clear Glass Vial with Pink Flip-Off Seal (Box of 1’s) | RxVAT-exempt | Admac LifesciencesIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY45366 | May 4, 2031 | |
EbedoxoDoxorubicin Hydrochloride | 10 mg/5 mL (2 mg/mL) Solution for Injection (I.V./I.A./Intravesicular)Amber Glass Vial with rubber stopper and red flip-off cap x 5mL Box of 1's | RxVAT-exempt | Fareva Unterach GmbHAustria | Sandoz Philippines Corporation | DR-XY25424 | Jul 28, 2029 | |
Emidoxoru-50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for IV Injection/InfusionUSP Type I Clear and Colorless Glass Vial with Pink Cover (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-8425-04 | Aug 8, 2028 | |
EorubicinDoxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV Infusion)Clear Glass vial with Aluminum Flip-Off Seal Cap x 1's (Box of 1's) | RxVAT-exempt | Zee Laboratories LimitedIndia | Importer: Eon Pharmatek Inc. | DR-XY47701 | Feb 15, 2027 | |
EorubicinDoxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV Infusion)Clear Glass vial with Aluminum Flip-Off Seal Cap x 1's (Box of 1’s) | RxVAT-exempt | Zee Laboratories LimitedIndia | Importer: Eon Pharmatek Inc. | DRP-15058 | Feb 15, 2027 | |
Fin-Dox 50Doxorubicin hydrochloride | 2 mg/mL (50 mg/25 mL) Solution for IV Injection25mL in 30mL capacity type I Amber colored glass vial with butyl rubber stopper and aluminum seal with red polypropylene flip-off cap (net content) (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | Finstad Inc. | DRP-13790 | Apr 20, 2028 | |
Haelan-50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (IV)Flint Tubular Type I Glass Vial x 25 mL with 20 mm Slotted GBBR Stopper and sealed with White Flip-off Aluminum Seal (Box of 1's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Kaufmann Pharma Inc.Importer: Medethix, Inc. | DRP-10197-01 | Oct 1, 2031 | |
Lipo-DoxDoxorubicin Hydrochloride | 2 mg/mL Solution for InjectionUSP Type I Glass Vial x 10 mL (Box of 10's) | RxVAT-exempt | TTY Biopharm Company Limited Chungli FactoryTaiwan | Onco Care Pharma CorporationImporter: American Taiwan Biopharma Phil. Inc, | DR-XY41292 | Oct 23, 2027 | |
Lippod 20Doxorubicin Hydrochloride | 2 mg/mL (20mg/ 10mL) Solution for Liposomal Injection (IV)10 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E, Medica, Inc. | DRP-11180 | Feb 9, 2027 | |
Lippod 50Doxorubicin Hydrochloride | 2 mg/mL (50 mg/25mL) Solution for Liposomal Injection (IV)30 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of l's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E, Medica, Inc. | DRP-11181 | Feb 9, 2027 | |
LypodoxoDoxorubicin Hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial in 10 mL (net content) (Box of 1’s) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Genace Pharma DistributorImporter: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd. | DRP-7095-01 | Jan 16, 2032 | |
Metodox 10Doxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV)USP Type I Flint Tubular Glass Vial (Box of 1's) | RxVAT-exempt | Neon Laboratories Ltd.India | Ambica International Corporation | DRP-6037 | Feb 11, 2029 | |
Metodox 50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (I.V.)USP Type I Flint Tubular Glass Vial (Box of 1's) | RxVAT-exempt | Neon Laboratories Ltd.India | Ambica International Corporation | DRP-6038 | Feb 11, 2029 | |
NatdoxDoxorubicin Hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Net Content) (Box of 1’s) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Natco Lifesciences Philippines Inc.Importer: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd. | DRP-7095-04 | Jan 16, 2027 | |
Natdox-LPDoxorubicin Hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrate Solution for I.V. InfusionUSP Type I Transparent Tubular Glass Vial with 20 mm Grey Bromobutyl Rubber Stopper and 20 mm Aluminum Flip-off Seals with Dark Blue Colour Button x 10 mL (Box of 1's) | RxVAT-exempt | Natco Pharma Limited (Pharma Division)India | Natco Lifesciences Philippines Inc. | DRP-9235 | Oct 16, 2030 | |
Natdox-LpDoxorubicin Hydrochloride | 2 mg/mL (50 mg/25 mL) Pegylated Liposomal Concentrate Solution for Injection for I.V. InfusionUSP Type I Transparent Tubular Glass Vial with 20 mm Grey Bromobutyl Rubber Stopper and 20 mm Aluminum Flip-off Seals with Dark Red Colour Button x 25 mL (Box of 1's) | RxVAT-exempt | Natco Pharma LimitedIndia | Natco Lifesciences Philippines Inc. | DRP-9234 | Oct 16, 2030 | |
NoneDoxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-2299-01 | Jul 2, 2028 | |
NoneDoxorubicin hydrochloride | 2 mg/mL Solution for Injection (I.V.)30 mL Type I Amber Glass Vial with Net Content of 25 mL (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4794-04 | Oct 7, 2028 | |
NoneDoxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (I.V.)30 mL-Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Magenta colored Aluminum Flip-Off Seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc. | DRP-13423-01 | Feb 15, 2028 | |
NoneDoxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial with Rubber Stopper and Red Flip-off Seal (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix, Inc.Importer: I.E. Medica, Inc. | DRP-2300-01 | Jul 2, 2028 | |
Nudoxa PEGDoxorubicin hydrochloride | 2 mg/mL Pegylated Liposomal Concentrate for Solution for IV InfusionUSP Type I Clear Glass Vial with Rubber Stopper and Violet colored Flip-Off Seal x 10 mL (Box of 1's) | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-13138 | Dec 6, 2032 | |
Oncurexin-10Doxorubicin hydrochloride | 10 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-10988 | Dec 29, 2031 | |
Oncurexin-50Doxorubicin hydrochloride | 50 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type I colorless glass vial with rubber plug and sealed with magenta color flip-off seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Ambica International CorporationTrader: Unicare Healthsciences Pvt. Ltd. | DRP-10968 | Dec 27, 2031 | |
Oxoru-10Doxorubicin Hydrochloride | 2 mg/mL (10 mg/5 mL) Solution for Injection (I.V.)USP Type I Amber-Colored Tubular Glass Vial Sealed With 20 mm Grey Bromo Butyl Rubber Plug, Aluminum Seal, And 20 mm Red Flip Off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Venus Remedies Ltd.India | Genace Pharma DistributorImporter: Aglobal Care, Inc. | DRP-9148 | Sep 18, 2030 | |
Oxoru-50Doxorubicin Hydrochloride | 2 mg/mL (50 mg/25 mL) Solution for Injection (I.V.)USP Type I Amber-Colored Tubular Glass Vial Sealed With 20 mm Grey Bromo Butyl Rubber Plug, Aluminum Seal, And 20 mm Red Flip Off Cap X 25 mL (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | Genace Pharma DistributorImporter: Aglobal Care, Inc. | DRP-9229 | Oct 14, 2030 | |
PaxorubicinDoxorubicin hydrochloride | 2 mg/ml Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net content of 5 mL and 25 mL, respectively (Box of 1’s) | RxVAT-exempt | Getwell PharmaceuticalsIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-4794-03 | Oct 7, 2028 | |
PegilyxDoxorubicin hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Suspension for Intravenous InfusionType I borosilicate glass tubular injection vial with butyl rubber stopper x 10 mL (net content). (Box of 1’s) | RxVAT-exempt | CSPC Ouyi Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-8744 | Mar 12, 2031 | |
PegpaxorubicinDoxorubicin Hydrochloride | 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrated Solution for I.V. InfusionUSP Type I Flint Tubular Glass Vial x 10 mL (Box of 1’s) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: BDR Pharmaceuticals Int’l Pvt. Ltd. | DRP-7095-02 | Jan 16, 2032 | |
RubicinDoxorubicin HCl | 10 mg Lyophilized Powder for Intravenous Injection10 mL USP Type I Clear Glass Vial with Red Flip-off Seal (Box of 1's) | RxVAT-exempt | Beacon Pharmaceuticals LimitedBangladesh | UNILAB, IncImporter: UNILAB, Inc. | DR-XY42578 | Sep 6, 2028 | |
RubicinDoxorubicin HCl | 50 mg Lyophilized Powder for Intravenous Injection50 mL USP Type I Clear Glass Vial with Red Flip-off Seal (Box of 1's) | RxVAT-exempt | Beacon Pharmaceuticals LimitedBangladesh | UNILAB, Inc. | DR-XY42579 | Sep 6, 2028 | |
RubisarDoxorubicin hydrochloride | 2 mg/mL Concentrate Solution for I.V. InfusionType I borosilicate colorless glass vial in 5 mL and 25 mL (net content) Box of 1's | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Company LimitedChina | Oncolife Corporation | DR-XY46718 | Sep 18, 2029 | |
RuxodoxDoxorubicin hydrochloride | 2 mg/ml Solution for Injection (I.V.)5 mL and 30 mL Type I Amber Glass Vial with Net Content of 5 mL and 25 mL Box of 1’s | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ellebasy Medicale TradingImporter: Ambica International Corporation | DRP-4794-01 | Oct 7, 2028 | |
Thrabene 10Doxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | Medethix Inc.Importer: I.E Medica Inc. | DRP-2299-02 | Jul 2, 2028 | |
Thrabene 50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial with Rubber Stopper and Red Flip-off Seal (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | MedEthix Inc.Importer: I.E Medica Inc. | DRP-2300-02 | Jul 2, 2028 | |
XorugenDoxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (I.V.)30 mL -Capacity USP Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Magenta colored Aluminum Flip-Off Seal (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Genace Pharma DistributorImporter: Suhitas Pharmaceuticals Inc. | DRP-13423-02 | Feb 15, 2028 | |
Xorutic-10Doxorubicin Hydrochloride | 10 mg Lyophilized Powder for Injection (IV)10 mL USP Type I Clear Glass Vial (Box of 1 's) | RxVAT-exempt | Adley Formulations Pvt. Ltd.India | ASA Life Philippines Limited Inc | DRP-5772 | Nov 19, 2028 | |
Xorutic-50Doxorubicin Hydrochloride | 50 mg Lyophilized Powder for Injection (IV)30 mL USP Type I Clear Glass Vial (Box of 1's) | RxVAT-exempt | Adley Formulations Pvt. Ltd.India | ASA Life Philippines Limited Inc | DRP-5773 | Nov 19, 2029 | |
Zodox-50Doxorubicin | 2 mg/mL (50 mg/25 mL) Concentrate Solution for IV InfusionClear molded glass vial with 20mm chlorobutyl rubber stopper and 20mm aluminum flip off pink seal x 25 mL (Box of 1s) | RxVAT-exempt | INTAS PHARMACEUTICALS LIMITEDIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8378 | Sep 18, 2029 | |
(no brand name)Doxorubicin Hydrochloride | 2 mg/mL (20mg/ 10mL) Solution for Liposomal Injection (IV)10 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of l's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E, Medica, Inc. | DRP-11141 | Feb 8, 2027 | |
(no brand name)Doxorubicin Hydrochloride | 2 mg/mL (50mg/25mL) Solution for Liposomal Injection (IV)30 mL USP Type I Borosilicate Glass Vial with Rubber Stopper (Box of 1's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E, Medica, Inc. | DRP-11140 | Feb 8, 2027 | |
(no brand name)Doxorubicin Hydrochloride | 2mg/mL (50mg/25mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass vial with rubber stopper and aluminum seal and polypropylene flip off cap x 25 mL (Box of 1's) | RxVAT-exempt | Venus Remedies, LimitedIndia | VE Pharma, Inc.Trader: Vexxa Life Sciences Pvt Ltd. | DR-XY48626 | Feb 14, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Doxorubicin Hydrochloride Injection: o 10 mg/5 mL, 20 mg/10 mL and 50 mg/25 mL (2 mg/mL) clear red solution in a single-dose vial o 150 mg/75 mL and 200 mg/100 mL (2 mg/mL) clear red solution in a multiple-dose vial Injection: o 10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL in single-dose vial (3) o 150 mg/75 mL, and 200 mg/100 mL in multiple-dose vial (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- • Radiation-Induced Toxicity: Can be increased by the administration of Doxorubicin Hydrochloride Injection. Radiation recall can occur in patients who receive Doxorubicin Hydrochloride Injection after prior radiation therapy. (5.7)
- • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and on the use of effective contraception. Advise males with female partners of reproductive potential to use effective contraception. Advise males with pregnant partners to use condoms. (5.8, 8.1, 8.3)
5.1 Cardiomyopathy and Arrhythmias
5.1 Cardiomyopathy and Arrhythmias Cardiomyopathy Doxorubicin hydrochloride can result in myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy is generally proportional to the cumulative exposure. Include prior doses of other anthracyclines or anthracenediones in calculations of total cumulative dosage for doxorubicin hydrochloride.
Cardiomyopathy may develop during treatment or up to several years after completion of treatment and can include decrease in LVEF and signs and symptoms of congestive heart failure (CHF). The probability of developing cardiomyopathy is estimated to be 1 to 2% at a total cumulative dose of 300 mg/m 2 of doxorubicin hydrochloride, 3 to 5% at a dose of 400 mg/m 2, 5 to 8% at a dose of 450 mg/m 2, and 6 to 20% at a dose of 500 mg/m 2, when doxorubicin hydrochloride is administered every 3 weeks.
There is an additive or potentially synergistic increase in the risk of cardiomyopathy in patients who have received radiotherapy to the mediastinum or concomitant therapy with other known cardiotoxic agents, such as cyclophosphamide and trastuzumab. Pericarditis and myocarditis have also been reported during or following doxorubicin hydrochloride treatment.
Assess left ventricular cardiac function (e.g., MUGA or echocardiogram) prior to initiation of Doxorubicin Hydrochloride Injection, during treatment to detect acute changes, and after treatment to detect delayed cardiotoxicity. Increase the frequency of assessments as the cumulative dose exceeds 300 mg/m 2. Use the same method of assessment of LVEF at all time points [see Use in Specific Populations (8.4)].
Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy [see Dosage and Administration (2.3)]. Consider the use of dexrazoxane to reduce the incidence and severity of cardiomyopathy due to doxorubicin hydrochloride administration in patients who have received a cumulative doxorubicin hydrochloride dose of 300 mg/m 2 and who will continue to receive doxorubicin hydrochloride.
Arrhythmias Doxorubicin hydrochloride can result in arrhythmias, including life-threatening arrhythmias, during or within a few hours after doxorubicin hydrochloride administration and at any time point during treatment. Tachyarrhythmias, including sinus tachycardia, premature ventricular contractions, and ventricular tachycardia, as well as bradycardia, can occur.
Electrocardiographic changes, including non-specific ST-T wave changes, atrioventricular and bundle-branch block can also occur. These electrocardiographic changes may be transient and self-limited and may not require a dosage modification of doxorubicin hydrochloride.
5.2 Secondary Malignancies
5.2 Secondary Malignancies The risk of developing secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) is increased following treatment with doxorubicin hydrochloride. Cumulative incidences ranged from 0.2% at five years to 1.5% at 10 years in two separate trials involving the adjuvant treatment of women with breast cancer.
These leukemias generally occur within 1 to 3 years of treatment.
5.3 Extravasation and Tissue Necrosis
5.3 Extravasation and Tissue Necrosis Extravasation of doxorubicin hydrochloride can cause severe local tissue injury manifesting as blistering, ulceration, and necrosis requiring wide excision of the affected area and skin grafting. Extravasation should be considered if a patient experiences a burning or stinging sensation or shows other evidence indicating peri-venous infiltration or extravasation; however, extravasation may be present in patients who do not experience a stinging or burning sensation or when blood return is present on aspiration of the infusion needle.
When given via a peripheral venous line, infuse Doxorubicin Hydrochloride Injection over 10 minutes or less to minimize the risk of thrombosis or perivenous extravasation. If extravasation is suspected, immediately discontinue the intravenous injection or continuous intravenous infusion [see Dosage and Administration (2.5)].
Apply ice to the site intermittently for 15 minutes, 4 times a day for 3 days. In adults, if appropriate, administer dexrazoxane at the site of extravasation as soon as possible and within the first 6 hours after extravasation.
5.4 Severe Myelosuppression
5.4 Severe Myelosuppression Doxorubicin hydrochloride can cause myelosuppression. In Study 1, the incidence of severe myelosuppression was: grade 4 leukopenia (0.3%), grade 3 leukopenia (3%), and grade 4 thrombocytopenia (0.1%). A dose-dependent, reversible neutropenia is the predominant manifestation of myelosuppression from doxorubicin hydrochloride.
When doxorubicin hydrochloride is administered every 21 days, the neutrophil count reaches its nadir 10 to 14 days after administration with recovery usually occurring by day 21. Obtain complete blood counts prior to each treatment and carefully monitor patients during treatment for possible clinical complications due to myelosuppression.
Delay next dose of Doxorubicin Hydrochloride Injection if severe myelosuppression has not improved. Consider dose reduction for patients with prolonged myelosuppression based on severity of reaction.
5.5 Use in Patients with Hepatic Impairment
5.5 Use in Patients with Hepatic Impairment The clearance of doxorubicin is decreased in patients with elevated serum bilirubin with an increased risk of toxicity [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)]. Doxorubicin Hydrochloride Injection is contraindicated in patients with severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Contraindications (4)].
Reduce the dose of Doxorubicin Hydrochloride Injection in patients with serum bilirubin levels of 1.2 to 5 mg/dL [see Dosage and Administration (2.4)]. Obtain liver tests including ALT, AST, alkaline phosphatase, and bilirubin prior to and during therapy.
5.6 Tumor Lysis Syndrome
5.6 Tumor Lysis Syndrome Doxorubicin hydrochloride can induce tumor lysis syndrome in patients with rapidly growing tumors. Evaluate blood uric acid levels, potassium, calcium, phosphate, and creatinine after initial treatment. Hydration, urine alkalinization, and prophylaxis with allopurinol to prevent hyperuricemia may minimize potential complications of tumor lysis syndrome.
5.7 Potentiation of Radiation Toxicity
5.7 Potentiation of Radiation Toxicity and Radiation Recall Doxorubicin hydrochloride can increase radiation-induced toxicity to the myocardium, mucosa, skin, and liver. Radiation recall, including but not limited to cutaneous and pulmonary toxicity, can occur in patients who receive doxorubicin hydrochloride after prior radiation therapy.
5.8 Embryo-Fetal Toxicity
5.8 Embryo-Fetal Toxicity Based on findings in animals and its mechanism of action, Doxorubicin Hydrochloride Injection can cause fetal harm when administered to a pregnant woman; avoid the use of Doxorubicin Hydrochloride Injection during the 1 st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2 nd and 3 rd trimesters.
Doxorubicin hydrochloride was teratogenic and embryotoxic in rats and rabbits at doses lower than the recommended human dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Doxorubicin Hydrochloride Injection and for 6 months after treatment.
Advise males with female partners of reproductive potential to use effective contraception during treatment with Doxorubicin Hydrochloride Injection and for 3 months after treatment. Advise males with pregnant partners to use condoms during treatment with Doxorubicin Hydrochloride Injection and for at least 10 days after the final dose [see Use in Specific Populations (8.1, 8.3), Nonclinical Toxicology (13.1)].
Drug interactions
- • Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp (7.1)
- • Do not administer doxorubicin hydrochloride in combination with trastuzumab due to increased risk of cardiac dysfunction (5.1, 7.2)
7.1 Effect of Other Drugs on Doxorubicin Hydrochloride Injection Inhibitors of CYP3A4,…
7.1 Effect of Other Drugs on Doxorubicin Hydrochloride Injection Inhibitors of CYP3A4, CYP2D6, and P-gp Concomitant use of doxorubicin hydrochloride with inhibitors of CYP3A4, CYP2D6, or P-glycoprotein (P-gp), increased concentrations of doxorubicin, which may increase the incidence and severity of adverse reactions of doxorubicin hydrochloride. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp.
Inducers of CYP3A4, CYP2D6, or P-gp Concomitant use of doxorubicin hydrochloride with inducers of CYP3A4, CYP2D6, or P-gp may decrease the concentration of doxorubicin. Avoid concomitant use of Doxorubicin Hydrochloride Injection with inducers of CYP3A4, CYP2D6, or P-gp. Paclitaxel Paclitaxel, when given prior to doxorubicin hydrochloride, increases the plasma-concentrations of doxorubicin and its metabolites.
Administer Doxorubicin Hydrochloride Injection prior to paclitaxel if used concomitantly.
7.2 Concomitant Use of Trastuzumab
7.2 Concomitant Use of Trastuzumab Concomitant use of trastuzumab and doxorubicin hydrochloride results in an increased risk of cardiac dysfunction. Avoid concomitant administration of Doxorubicin Hydrochloride Injection and trastuzumab [see Warnings and Precautions (5.1)]. Patients receiving doxorubicin after stopping treatment with trastuzumab may also be at an increased risk of developing cardiotoxicity.
Trastuzumab may persist in the circulation for up to 7 months. Therefore, avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab when possible. If anthracyclines are used before this time, carefully monitor cardiac function.
7.3 Concomitant Use of Dexrazoxane
7.3 Concomitant Use of Dexrazoxane Do not administer dexrazoxane as a cardioprotectant at the initiation of doxorubicin hydrochloride-containing chemotherapy regimens. In a randomized trial in women with metastatic breast cancer, initiation of dexrazoxane with doxorubicin hydrochloride-based chemotherapy resulted in a significantly lower tumor response rate (48% vs. 63%; p = 0.007) and shorter time to progression compared to doxorubicin hydrochloride-based chemotherapy alone.
7.4 Concomitant Use of 6
7.4 Concomitant Use of 6-Mercaptopurine Doxorubicin hydrochloride may potentiate 6-mercaptopurine-induced hepatotoxicity. In 11 patients with refractory leukemia treated with 6-mercaptopurine (500 mg/m 2 intravenously daily for 5 days per cycle every 2–3 weeks) and doxorubicin hydrochloride (50 mg/m 2 intravenous once per cycle every 2–3 weeks) alone or with vincristine and prednisone, all developed hepatic dysfunction manifested by increased total serum bilirubin, alkaline phosphatase and aspartate aminotransferase.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp.
Avoid concomitant use of Doxorubicin Hydrochloride Injection with inhibitors of CYP3A4, CYP2D6, or P-gp.
Inducers of CYP3A4, CYP2D6, or P-gp Concomitant use of doxorubicin hydrochloride with inducers of CYP3A4, CYP2D6, or P-gp may decrease the concentration of doxorubicin.
Avoid concomitant use of Doxorubicin Hydrochloride Injection with inducers of CYP3A4, CYP2D6, or P-gp.
Adverse reactions
- The following clinically significant adverse reactions are described elsewhere in the labeling. • Cardiomyopathy and Arrhythmias [see Warnings and Precautions (5.1)] • Secondary Malignancies [see Warnings and Precautions (5.2)] • Extravasation and Tissue Necrosis [see Warnings and Precautions (5.3)] • Severe Myelosuppression [see Warnings and Precautions (5.4)] • Tumor Lysis Syndrome [see Warnings and Precautions (5.6)] • Radiation Sensitization and Radiation Recall [see Warnings and Precautions (5.7)] The most common (>10%) adverse reactions are alopecia, nausea and vomiting. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Breast Cancer The safety data below were collected from 1492 women who received doxorubicin hydrochloride at a dose of 60 mg/m 2 and cyclophosphamide at a dose of 600 mg/m 2 (AC) every 3 weeks for 4 cycles for the adjuvant treatment of axillary lymph node positive breast cancer.
The median number of cycles received was 4. Selected adverse reactions reported in this study are provided in Table 2. No treatment-related deaths were reported in patients on either arm of the study. Table 2. Selected Adverse Reactions in Patients with Early Breast Cancer Involving Axillary Lymph Nodes Adverse Reactions AC Includes pooled data from patients who received either AC for 4 cycles or AC for 4 cycles followed by CMF for 3 cycles N = 1492 Conventional CMF N = 739 % % AC = doxorubicin hydrochloride, cyclophosphamide; CMF = cyclophosphamide, methotrexate, fluorouracil Alopecia 92 71 Vomiting Vomiting ≤12 hours 34 25 Vomiting >12 hours 37 12 Intractable 5 2 Leukopenia Grade 3 (1,000–1,999 /mm 3) 3.4 9.4 Grade 4 (<1000 /mm 3) 0.3 0.3 Shock, sepsis 2 1 Systemic infection 2 1 Cardiac dysfunction Asymptomatic 0.2 0.1 Transient 0.1 0 Symptomatic 0.1 0 Thrombocytopenia Grade 3 (25,000–49,999 /mm 3) 0 0.3 Grade 4 (<25,000 /mm 3) 0.1 0
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Doxorubicin Hydrochloride Injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiac – Cardiogenic shock Cutaneous – Skin and nail hyperpigmentation, oncolysis, rash, itching, photosensitivity, urticaria, acral erythema, palmar plantar erythrodysesthesia Gastrointestinal – Nausea, mucositis, stomatitis, necrotizing colitis, typhlitis, gastric erosions, gastrointestinal tract bleeding, hematochezia, esophagitis, anorexia, abdominal pain, dehydration, diarrhea, hyperpigmentation of the oral mucosa Hypersensitivity – Anaphylaxis Laboratory Abnormalities – Increased ALT, increased AST Neurological – Peripheral sensory and motor neuropathy, seizures, coma Ocular – Conjunctivitis, keratitis, lacrimation Vascular – Phlebosclerosis, phlebitis/thrombophlebitis, hot flashes, thromboembolism Other – Malaise/asthenia, fever, chills, weight gain
Adverse reaction frequency tables (US label) US FDA label
| Adverse Reactions | ACIncludes pooled data from patients who received either AC for 4 cycles or AC for 4 cycles followed by CMF for 3 cycles N = 1492 | Conventional CMF N = 739 |
|---|---|---|
| % | % | |
| AC = doxorubicin hydrochloride, cyclophosphamide; CMF = cyclophosphamide, methotrexate, fluorouracil | ||
| Alopecia | 92 | 71 |
| Vomiting | ||
| Vomiting ≤12 hours | 34 | 25 |
| Vomiting >12 hours | 37 | 12 |
| Intractable | 5 | 2 |
| Leukopenia | ||
| Grade 3 (1,000–1,999 /mm3) | 3.4 | 9.4 |
| Grade 4 (<1000 /mm3) | 0.3 | 0.3 |
| Shock, sepsis | 2 | 1 |
| Systemic infection | 2 | 1 |
| Cardiac dysfunction | ||
| Asymptomatic | 0.2 | 0.1 |
| Transient | 0.1 | 0 |
| Symptomatic | 0.1 | 0 |
| Thrombocytopenia | ||
| Grade 3 (25,000–49,999 /mm3) | 0 | 0.3 |
| Grade 4 (<25,000 /mm3) | 0.1 | 0 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings in animals and its mechanism of action, Doxorubicin Hydrochloride Injection can cause fetal harm when administered to a pregnant woman; avoid the use of Doxorubicin Hydrochloride Injection during the 1 st trimester. Available human data do not establish the presence or absence of major birth defects and miscarriage related to the use of doxorubicin hydrochloride during the 2 nd and 3 rd trimesters.
Doxorubicin hydrochloride was teratogenic and embryotoxic in rats and embryotoxic in rabbits when administered during organogenesis at doses approximately 0.07 times (based on body surface area) the recommended human dose of 60 mg/m 2 (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data Animal Data Doxorubicin hydrochloride was teratogenic and embryotoxic at doses of 0.8 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) when administered during the period of organogenesis in rats. Teratogenicity and embryotoxicity were also seen using discrete periods of treatment.
The most susceptible was the 6- to 9-day gestation period at doses of 1.25 mg/kg/day and greater. Characteristic malformations included esophageal and intestinal atresia, tracheo-esophageal fistula, hypoplasia of the urinary bladder, and cardiovascular anomalies. Doxorubicin hydrochloride was embryotoxic (increase in embryo‑fetal deaths) and abortifacient at 0.4 mg/kg/day (about 0.07 times the recommended human dose based on body surface area) in rabbits when administered during the period of organogenesis.
Mechanism of action
12.1 Mechanism of Action The cytotoxic effect of doxorubicin hydrochloride on malignant cells and its toxic effects on various organs are thought to be related to nucleotide base intercalation and cell membrane lipid binding activities of doxorubicin. Intercalation inhibits nucleotide replication and action of DNA and RNA polymerases. The interaction of doxorubicin with topoisomerase II to form DNA-cleavable complexes appears to be an important mechanism of doxorubicin hydrochloride cytocidal activity.
US FDA labelPharmacokinetics
Distribution The distribution half-life is approximately 5 minutes.
The terminal half-life is 20 hours to 48 hours.
Disposition of doxorubicinol in patients is formation rate limited, with the terminal half-life of doxorubicinol being similar to doxorubicin.
Excretion Plasma clearance is predominately by metabolism and biliary excretion.
However, the terminal half-life of doxorubicin was longer in men compared to women (54 versus 35 hours).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Pharmacokinetic studies conducted in patients with various types of tumors have shown that doxorubicin follows multiphasic disposition after intravenous injection. In four patients, doxorubicin demonstrated dose-independent pharmacokinetics across a dose range of 30 mg/m 2 to 70 mg/m 2. Distribution The distribution half-life is approximately 5 minutes.
Steady-state distribution volume ranges from 809 L/m 2 to 1214 L/m 2. Binding of doxorubicin and its major metabolite, doxorubicinol, to plasma proteins is 75% and is independent of plasma concentration of doxorubicin up to 1.1 µg/mL. Doxorubicin does not cross the blood brain barrier. Elimination Plasma clearance is ranges from 324 mL/min/m 2 to 809 mL/min/m 2.
The terminal half-life is 20 hours to 48 hours. Metabolism Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp. Enzymatic reduction at the 7 position and cleavage of the daunosamine sugar yields aglycones which are accompanied by free radical formation, the local production of which may contribute to the cardiotoxic activity of doxorubicin hydrochloride.
Disposition of doxorubicinol in patients is formation rate limited, with the terminal half-life of doxorubicinol being similar to doxorubicin. The relative exposure of doxorubicinol, i.e., the ratio between the AUC of doxorubicinol and the AUC of doxorubicin is approximately 0.5. Excretion Plasma clearance is predominately by metabolism and biliary excretion.
Approximately 40% of the dose appears in the bile in 5 days, while only 5% to 12% of the drug and its metabolites appear in the urine during the same time period. In urine, <3% of the dose was recovered as doxorubicinol over 7 days. Specific Populations Weight Systemic clearance of doxorubicin is significantly reduced in obese women with ideal body weight greater than 130%.
There was a significant reduction in clearance without any change in volume of distribution in obese patients when compared with normal patients with less than 115% ideal body weight. Pediatric Patients Following administration of doses ranging from 10 mg/m 2 to 75 mg/m 2 of doxorubicin hydrochloride to 60 patients ranging from 2 months to 20 years, doxorubicin clearance averaged 1443 ± 114 mL/min/m 2.
Further analysis demonstrated that clearance in 52 patients ranging from 2 to 20 years (1540 mL/min/m 2) was increased compared with adults. However, clearance in infants younger than 2 years of age (813 mL/min/m 2) was decreased compared with older patients (ranging from 2 to 20 years) and approached the range of clearance values determined in adults [see Use in Specific Populations (8.4)].
Sex A published clinical study involving 6 men and 21 women with no prior anthracycline therapy reported a significantly higher median doxorubicin clearance in men compared to women (1088 mL/min/m 2 versus 433 mL/min/m 2). However, the terminal half-life of doxorubicin was longer in men compared to women (54 versus 35 hours).
Patients with Hepatic Impairment The clearance of doxorubicin and doxorubicinol was reduced in patients with elevated serum total bilirubin concentrations [see Dosage and Administration (2.4), Warnings and Precautions (5.5)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Doxorubicin 2 mg/mL, 25 mL Vial | ₱396.00–₱725.00Reference ₱484.00 | per vial | DPRI procurement range |
| Doxorubicin 2 mg/mL, 5 mL Vial | ₱151.00–₱166.00Reference ₱151.00 | per vial | DPRI procurement range |
| Doxorubicin 10 mg powder Vial | ₱160.00–₱425.00Reference ₱160.00 | per vial | DPRI procurement range |
| Doxorubicin 50 mg powder Vial | ₱440.20–₱678.00Reference ₱440.20 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Doxorubicin (as hydrochloride) |
| PNF listing | Inj.: powder, 10 mg and 50 mg vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 2 mg/mL, 5 mL and 25 mL vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Doxorubicin Hydrochloride · Pfizer Laboratories Div Pfizer Inc [US FDA-approved label, version 28, May 5, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fd148fb-0fbc-4b6f-b790-23546fb46a71
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .